Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 0.56 |
| ▸ | DNA2 | P51530 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249310 | 0.80 | DNA2 (0.67) | FBP1DNA2CASP6CTDSP1PARP1 | |
| SCHEMBL4171570 | 0.77 | KDM4E (0.47) | PARP1NPC1MAPTMAPK1 | |
| SCHEMBL4161885 | 0.77 | PARP1 (0.45) | PARP1MAPT | |
| SCHEMBL18509141 | 0.75 | FBP1 (0.51) | FBP1 | |
| SCHEMBL18509859 | 0.75 | FBP1 (0.48) | FBP1DNA2CASP6CTDSP1 | |
| SCHEMBL18509279 | 0.74 | FBP1 (0.47) | FBP1DNA2CASP6CTDSP1 | |
| SCHEMBL18509513 | 0.74 | FBP1 (0.60) | FBP1DNA2CASP6CTDSP1 | |
| SCHEMBL18509498 | 0.74 | FBP1 (0.47) | FBP1 | |
| SCHEMBL18509692 | 0.74 | FBP1 (0.47) | FBP1DNA2CASP6CTDSP1 | |
| SCHEMBL3245558 | 0.74 | CLEC4M (0.52) | FBP1DNA2CASP6CTDSP1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | FBP1 1900/4885DNA2 3006/4885CASP6 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.